[1] Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344-1354.
[2] Sun HC, Zhu XD, Zhou J, et al. Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. Ann Transl Med. 2020;8(20):1301.
[3] Chen J, Lu L, Wen T, et al. 2021 ESMO 945P - Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE):Updated results from a multi-center prospective cohort study[J]. Ann Oncol, 2021, 32(5S):S818-S828.
[4] Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).DOI: 10.1200/JCO.2021.39.15_suppl.1000IF:45.3
[5] 944P Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC II and III stage: A single-center prospective phase II trial.
[6] Bai S, Hu L, Liu J, Sun M, Sun Y, Xue F. Prognostic Nomograms Combined Adjuvant Lenvatinib for Hepatitis B Virus-related Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection. Front Oncol. 2022;12:919824. Published 2022 Jul 11. doi:10.3389/fonc.2022.919824IF: 4.7 Q2 B3
[7] 张珅瑜,等. 中国实用外科杂志,2023,43(4):401-404.
[8] Chow P, Chen M, Cheng A-L, et al. IMbrave050: phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma at high risk of disease recurrence following resection or ablation. Presented at: 2023 AACR Annual Meeting; April 14-19, 2023; Orlando, Florida. Abstract CT003.